(Q36623326)

15 August 2017

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes (English)

1 reference

15 August 2017

A Håkansson

1

1 reference

15 August 2017

B Gustafsson

2

1 reference

15 August 2017

L Krysander

3

1 reference

15 August 2017

B Hjelmqvist

4

1 reference

15 August 2017

B Rettrup

5

1 reference

15 August 2017

L Håkansson

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

85

1 reference

15 August 2017

12

1 reference

15 August 2017

1871-1877

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

15 August 2017

start time

1 December 2001

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1054/bjoc.2001.2169

0 references

cites work

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Histologic regression in malignant melanoma: an interobserver concordance study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Model predicting survival in stage I melanoma based on tumor progression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Spontaneous regression of melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95).

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364006

Thin malignant melanomas with regression and metastases

21 October 2018

1 reference

12 December 2020

On down-regulation of the immune response to metastatic malignant melanoma

1 reference

12 December 2020

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

12 December 2020

Regulation of monocyte-derived interleukin 1 receptor antagonist by cisplatinum

1 reference

12 December 2020

Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response

1 reference

12 December 2020

Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF

1 reference

12 December 2020

Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy

1 reference

12 December 2020

Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma

1 reference

12 December 2020

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

12 December 2020

A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mito

1 reference

12 December 2020

Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases

1 reference

12 December 2020

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2001.2169

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference